However, the decline in sensitivity to SFN limits its efficacy in improving survival time.4 Recent studies have reported that the AKT/ERK pathway is involved in HCC sensitivity to SFN,5,6 and our data demonstrated that DDX24 could regulate the expression of phospho-AKT and phospho-ERK. The gene discussed is AKT1; the disease is hepatocellular carcinoma.